Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.5%

2 terminated out of 80 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

15%

6 of 40 completed with results

Key Signals

6 with results95% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (18)
P 1 (8)
P 2 (15)
P 3 (2)
P 4 (4)

Trial Status

Completed40
Unknown16
Recruiting9
Active Not Recruiting7
Withdrawn4
Terminated2

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 40 completed trials

Clinical Trials (80)

Showing 20 of 20 trials
NCT06640387Active Not RecruitingPrimary

CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools

NCT06950177Phase 1Active Not Recruiting

Pancoronavirus Vaccine Study in Healthy Adults

NCT05359991Not ApplicableRecruiting

Exercise in Child Health

NCT06234956Phase 2CompletedPrimary

Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

NCT07408297Phase 2Completed

Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda

NCT06065176Phase 4Completed

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

NCT07189936Phase 2Recruiting

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

NCT05421208Not ApplicableRecruiting

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

NCT06548841Completed

Development and Validation of (Bio)Sensors for the Identification of Pathogens

NCT05205746Phase 2CompletedPrimary

Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence

NCT07197164Phase 2Recruiting

Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

NCT05303402Phase 2CompletedPrimary

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

NCT05292274Recruiting

NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

NCT06283459Phase 1CompletedPrimary

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

NCT05973084RecruitingPrimary

COVID-19 Transmission and Morbidity in Malawi

NCT05667597Not ApplicableActive Not RecruitingPrimary

Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

NCT06997653Phase 2Withdrawn

Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women

NCT05467930Recruiting

CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2

NCT05467917Active Not Recruiting

ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases

NCT05443607Active Not RecruitingPrimary

Transplacental Transmission of RSV (TTRSV)

Scroll to load more

Research Network

Activity Timeline